Summary
72.93 0.68(0.94%)10/04/2024
Intra-Cellular Therapies Inc (ITCI)
Intra-Cellular Therapies Inc (ITCI)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.87 | -0.52 | 0.32 | 4.86 | 8.52 | 43.25 | 793.75 | 386.20 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 72.93 | |
| Open | 72.71 | |
| High | 72.97 | |
| Low | 72.32 | |
| Volume | 176,014 | |
| Change | 0.63 | |
| Change % | 0.87 | |
| Avg Volume (20 Days) | 311,035 | |
| Volume/Avg Volume (20 Days) Ratio | 0.57 | |
| 52 Week Range | 45.50 - 84.89 | |
| Price vs 52 Week High | -14.09% | |
| Price vs 52 Week Low | 60.29% | |
| Range | 0.30 | |
| Gap Up/Down | -0.60 | |
Fundamentals | ||
| Market Capitalization (Mln) | 7,736 | |
| EBIDTA | -131,415,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 91.64 | |
| Book Value | 6.1500 | |
| Earnings Per Share | -1.1600 | |
| EPS Estimate Current Quarter | -0.3200 | |
| EPS Estimate Next Quarter | -0.2000 | |
| EPS Estimate Current Year | -0.5500 | |
| EPS Estimate Next Year | 1.0600 | |
| Diluted EPS (TTM) | -1.1600 | |
| Revenues | ||
| Profit Marging | -0.2157 | |
| Operating Marging (TTM) | -0.1446 | |
| Return on asset (TTM) | -0.1123 | |
| Return on equity (TTM) | -0.1807 | |
| Revenue TTM | 513,929,984 | |
| Revenue per share TTM | 5.3360 | |
| Quarterly Revenue Growth (YOY) | 0.5200 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 95,156,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 10.7836 | |
| Revenue Enterprise Value | 12.7585 | |
| EBITDA Enterprise Value | -37.1202 | |
| Shares | ||
| Shares Outstanding | 105,575,000 | |
| Shares Float | 103,340,891 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.04 | |
| Insider (%) | 2.32 | |
| Institutions (%) | 90.50 | |
09/23 08:00 EST - globenewswire.com
Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)
Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)
09/06 12:37 EST - zacks.com
Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?
Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?
08/28 08:00 EST - globenewswire.com
Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at three upcoming investor conferences:
Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at three upcoming investor conferences:
08/08 11:06 EST - investors.com
Biotech Stock Pulls Back After Earnings Report; Profits On The Horizon
This biotech stock is in a base and seeking support at a moving average. The company's losses are dwindling and analysts see profits coming.
Biotech Stock Pulls Back After Earnings Report; Profits On The Horizon
This biotech stock is in a base and seeking support at a moving average. The company's losses are dwindling and analysts see profits coming.
08/08 10:56 EST - zacks.com
Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat
Intra-Cellular (ITCI) reports second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat
Intra-Cellular (ITCI) reports second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
08/08 08:00 EST - globenewswire.com
Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference
NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024 at 12:00 p.m. ET in Boston, MA.
Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference
NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024 at 12:00 p.m. ET in Boston, MA.
08/07 09:46 EST - zacks.com
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.45 per share a year ago.
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.45 per share a year ago.
08/07 07:40 EST - globenewswire.com
Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sanjeev Narula will join the Company on August 12, 2024 and will serve as Executive Vice President, Chief Financial Officer. Mr. Narula will report to Dr. Sharon Mates, ITCI's Chairman and Chief Executive Officer. Lawrence Hineline, who currently serves as Chief Financial Officer, will retire on the same date but will continue to serve as a consultant to the Company for a period of time to ensure a smooth transition.
Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sanjeev Narula will join the Company on August 12, 2024 and will serve as Executive Vice President, Chief Financial Officer. Mr. Narula will report to Dr. Sharon Mates, ITCI's Chairman and Chief Executive Officer. Lawrence Hineline, who currently serves as Chief Financial Officer, will retire on the same date but will continue to serve as a consultant to the Company for a period of time to ensure a smooth transition.
08/07 07:30 EST - globenewswire.com
Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance
CAPLYTA Q2 2024 net product sales were $161.3 million, compared to $110.1 million for the same period in 2023, representing a 46% increase
Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance
CAPLYTA Q2 2024 net product sales were $161.3 million, compared to $110.1 million for the same period in 2023, representing a 46% increase
07/31 11:06 EST - zacks.com
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
07/24 08:00 EST - globenewswire.com
Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, August 7, 2024, to provide a corporate update and discuss details of the Company's financial results for the quarter ended June 30, 2024.
Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, August 7, 2024, to provide a corporate update and discuss details of the Company's financial results for the quarter ended June 30, 2024.
07/09 10:56 EST - zacks.com
Wall Street Analysts See a 30.14% Upside in Intra-Cellular (ITCI): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 30.1% in Intra-Cellular (ITCI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 30.14% Upside in Intra-Cellular (ITCI): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 30.1% in Intra-Cellular (ITCI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
06/24 10:55 EST - zacks.com
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
06/19 11:30 EST - zacks.com
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
06/19 07:30 EST - zacks.com
Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?
Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?
Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
06/19 02:08 EST - seekingalpha.com
Intra-Cellular Brightens MDD Outlook With Caplyta Success
Caplyta (lumateperone) shows significant promise as an adjunctive treatment for Major Depressive Disorder. Caplyta's unique pharmacological profile targeting serotonin, dopamine, and glutamate pathways sets it apart in the saturated MDD market. Intra-Cellular's financial stability is supported by strong sales growth and sufficient cash reserves to sustain operations until 2027.
Intra-Cellular Brightens MDD Outlook With Caplyta Success
Caplyta (lumateperone) shows significant promise as an adjunctive treatment for Major Depressive Disorder. Caplyta's unique pharmacological profile targeting serotonin, dopamine, and glutamate pathways sets it apart in the saturated MDD market. Intra-Cellular's financial stability is supported by strong sales growth and sufficient cash reserves to sustain operations until 2027.
06/18 10:37 EST - benzinga.com
Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study
Tuesday, Intra-Cellular Therapies Inc ITCI released topline results from Study 502 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD).
Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study
Tuesday, Intra-Cellular Therapies Inc ITCI released topline results from Study 502 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD).
06/18 07:30 EST - globenewswire.com
Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
In Study 502, lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
In Study 502, lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
06/10 08:00 EST - globenewswire.com
Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 45th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2024 at 10:00 a.m. ET in Miami, FL.
Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 45th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2024 at 10:00 a.m. ET in Miami, FL.
06/06 12:35 EST - zacks.com
Why Is Intra-Cellular (ITCI) Up 1.2% Since Last Earnings Report?
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?
Why Is Intra-Cellular (ITCI) Up 1.2% Since Last Earnings Report?
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?